Retrieving the latest stories.
The most consequential developments in technology and the world, selected against strict editorial criteria. Each is explained in twenty seconds.
Why it mattersSpaceX has told NASA it will stop flying Crew Dragon by 2030, stopped selling Falcon 9 launches after 2028, declined Space Force bids and refused launches for NASA lunar landers, showing the US government's dependence on one private contractor now shifting as…
Why it mattersEuropean governments, including the European Commission, are moving from debating digital sovereignty to deploying Matrix-based federated messaging at scale as an alternative to US-controlled tools like Teams, though the evidence is mostly conference-level ad…
Why it mattersReuters reports that Susquehanna, Jump Trading and Bloomberg bought a paid feed giving machines a 50ms head start on a sitting president's posts, a possible first for a presidential-linked business selling market-moving access, though the subscriber list rest…
Why it mattersA downgrade and the first combined revenue and earnings miss in nearly four years make the stock's reaction more significant.
Why it mattersGoogle is extending ads into conversational AI Mode across ten new markets and into follow-up turns in the US, showing monetization moving into AI answers, though the evidence is mostly Google's own claims.
Why it mattersThe EU's Pan-Arctic Cable plan, with an Arctic Cable Hub and routes that bypass the US, shows geopolitics now deciding where internet backbone cables go, though the project is still early-stage and faces funding and icebreaker hurdles.
Why it matters9B Hugging Face purchase would let it control a key distribution route for open AI models, extending a wider antitrust scrutiny of Nvidia's chip dominance, though the report rests on two anonymous sources and no formal action yet.
Why it mattersHHS used an enforcement-discretion rule, published in the Federal Register, to let compounding pharmacies sell six peptides the FDA removed over safety concerns, bypassing the formal process and weakening the evidence gate for unproven drugs.
Why it mattersThe buyout offer to about a quarter of Microsoft's workforce links its heavy AI spending to job cuts, so the story is more than an earnings item.